Your browser doesn't support javascript.
loading
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Castinetti, Frédéric; Albarel, Frédéric; Archambeaud, Françoise; Bertherat, Jérome; Bouillet, Benjamin; Buffier, Perrine; Briet, Claire; Cariou, Bertrand; Caron, Philippe; Chabre, Olivier; Chanson, Philippe; Cortet, Christine; Do Cao, Christine; Drui, Delphine; Haissaguerre, Magali; Hescot, Ségolène; Illouz, Frédéric; Kuhn, Emmanuelle; Lahlou, Najiba; Merlen, Emilie; Raverot, Véronique; Smati, Sarra; Verges, Bruno; Borson-Chazot, Françoise.
Afiliação
  • Castinetti F; Aix Marseille Université, INSERM, U1251, Department of Endocrinology, Marseille Medical Genetics (MMG), centre de référence des maladies rares de l'hypophyse (HYPO), hôpital de la Conception, France, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France. Electronic address: Fred
  • Albarel F; Aix Marseille Université, INSERM, U1251, Department of Endocrinology, Marseille Medical Genetics (MMG), centre de référence des maladies rares de l'hypophyse (HYPO), hôpital de la Conception, France, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France.
  • Archambeaud F; Service de médecine interne B, endocrinologie, 87042 Limoges cedex, France.
  • Bertherat J; Service d'endocrinologie et maladies métaboliques, hôpital Cochin, 75674 Paris cedex 14, France.
  • Bouillet B; Service d'endocrinologie, diabétologie, maladies métaboliques, CHU de Dijon, hôpital François-Mitterrand, 21034 Dijon cedex, France; Unité Inserm LNC-UMR 1231, université de Bourgogne, 21000 Dijon, France.
  • Buffier P; Service d'endocrinologie, diabétologie, maladies métaboliques, CHU de Dijon, hôpital François-Mitterrand, 21034 Dijon cedex, France.
  • Briet C; Inserm U1083, Department of Endocrinology, Diabetology and Nutrition, Angers University, University Medical Center, Institut MITOVASC, 49000 Angers, France.
  • Cariou B; Department of Endocrinology, CHU de Nantes, institut du Thorax, 44000 Nantes, France.
  • Caron P; TSA 30030, service d'endocrinologie, maladies métaboliques, nutrition, CHU de Toulouse, hôpital Larrey, 30030 Toulouse cedex 9, France.
  • Chabre O; Service d'endocrinologie, diabétologie, nutrition, CHU de Grenoble, hôpital Albert-Michallon, 38043 Grenoble cedex 9, France.
  • Chanson P; UMR S-1185, service d'endocrinologie et des maladies de la reproduction, faculté de médecine Paris-Sud, université Paris-Saclay, hôpital de Bicêtre, Assistance publique des hôpitaux de Paris (AP-HP), 94275 Le Kremlin-Bicêtre, France.
  • Cortet C; Service d'endocrinologue, CHRU de Lille, hôpital Huriez, 59037 Lille cedex, France.
  • Do Cao C; Service d'endocrinologue, CHRU de Lille, hôpital Huriez, 59037 Lille cedex, France.
  • Drui D; Department of Endocrinology, CHU de Nantes, institut du Thorax, 44000 Nantes, France.
  • Haissaguerre M; Service d'endocrinologie, diabétologie et maladies métaboliques, CHU de Bordeaux, hôpital du Haut-Lévêque, 33604 Pessac cedex, France.
  • Hescot S; Oncologie endocrinienne, institut Curie, 92210 Saint-Cloud, France.
  • Illouz F; Department of Endocrinology, Diabetes and Nutrition, Reference Centre of Rare Thyroid Disease, Hospital of Angers, 49933 Angers cedex 09, France.
  • Kuhn E; UMR S-1185, service d'endocrinologie et des maladies de la reproduction, faculté de médecine Paris-Sud, université Paris-Saclay, hôpital de Bicêtre, Assistance publique des hôpitaux de Paris (AP-HP), 94275 Le Kremlin-Bicêtre, France.
  • Lahlou N; BPR-AS, département d'hormonologie spécialisée, 45700 Pannes, France.
  • Merlen E; Service d'endocrinologue, CHRU de Lille, hôpital Huriez, 59037 Lille cedex, France.
  • Raverot V; Laboratoire d'hormonologie, service de biochimie et biologie moléculaire, groupement hospitalier Est, hospices civils de Lyon, 69008 Lyon, France.
  • Smati S; Department of Endocrinology, CHU de Nantes, institut du Thorax, 44000 Nantes, France.
  • Verges B; Service d'endocrinologie, diabétologie, maladies métaboliques, CHU de Dijon, hôpital François-Mitterrand, 21034 Dijon cedex, France; Unité Inserm LNC-UMR 1231, université de Bourgogne, 21000 Dijon, France.
  • Borson-Chazot F; HESPER EA 7425, université Claude-Bernard Lyon 1, hospices civils de Lyon, fédération d'endocrinologie, 69008 Lyon, France.
Ann Endocrinol (Paris) ; 79(5): 591-595, 2018 Oct.
Article em En | MEDLINE | ID: mdl-30056975
ABSTRACT
The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Sistema Endócrino / Imunoterapia / Neoplasias / Antineoplásicos Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Sistema Endócrino / Imunoterapia / Neoplasias / Antineoplásicos Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article